Oruka Therapeutics, Inc. (ORKA): Cash & Equivalents
$46.94M
As of 2025-12-31
$268.47M
As of 2026-06-30
+3.4%
3-year compound annual growth
-0.9%
5-year compound annual growth
+1.9%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $46.94M | -23.8% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $61.58M | +64.5% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $37.43M | -11.8% | 2024-02-01, Balance as of period end |
| 2022-12-31 | $42.45M | -20.5% | 2024-02-01, Balance as of period end |
| 2021-12-31 | $53.36M | +8.7% | 2023-02-24, Balance as of period end |
| 2020-12-31 | $49.07M | +486.8% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $8.36M | +26.6% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $6.61M | -24.1% | 2020-02-18, Balance as of period end |
| 2017-12-31 | $8.70M | +17.6% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $7.40M | -80.9% | 2018-03-22, Balance as of period end |
| 2015-12-31 | $38.80M | +152.7% | 2017-03-21, Balance as of period end |
| 2014-12-31 | $15.35M | -8.4% | 2016-03-17, Balance as of period end |
| 2013-12-31 | $16.76M | +473.8% | 2015-03-19, Balance as of period end |
| 2012-12-31 | $2.92M | -50.9% | 2014-03-20, Balance as of period end |
| 2011-12-31 | $5.94M | -15.4% | 2014-03-20, Balance as of period end |
| 2010-12-31 | $7.03M | -9.5% | 2013-03-21, Balance as of period end |
| 2009-12-31 | $7.76M | n/a | 2012-03-27, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | $46.94M | -23.8% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $84.85M | -17.1% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $167.81M | +344.0% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $54.30M | -39.1% |
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | $46.73M | +22.2% |
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | $98.90M | -20.3% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $68.00M | +4.7% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $52.65M | -7.3% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $40.58M | -28.5% |
Compare ORKA, VNDA, TBPH, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗